These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29674328)

  • 1. Catastrophic circulatory collapse after inadvertent subcutaneous injection of treprostinil.
    Radosevich JJ; Dutt M; Feldman J
    Am J Health Syst Pharm; 2018 Jun; 75(11):768-772. PubMed ID: 29674328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Switch From Subcutaneous to Intravenous Treprostinil in Precapillary Pulmonary Hypertension by Pump Implantation.
    Steringer-Mascherbauer R; Maria L; Reinhold F; Elisabeth S; Charlotte H; Dagmar E; Uwe F; Josef A
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):38-42. PubMed ID: 33079830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
    Simonneau G; Barst RJ; Galie N; Naeije R; Rich S; Bourge RC; Keogh A; Oudiz R; Frost A; Blackburn SD; Crow JW; Rubin LJ;
    Am J Respir Crit Care Med; 2002 Mar; 165(6):800-4. PubMed ID: 11897647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable.
    El-Kersh K; Ruf KM; Smith JS
    Am J Ther; 2018; 25(2):e213-e217. PubMed ID: 27003321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
    Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R
    Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful management of an inadvertent excessive treprostinil overdose.
    Hohenforst-Schmidt W; Hornig J; Friedel N; Zarogoulidis P; Zarogoulidis K; Brachmann J
    Drug Des Devel Ther; 2013; 7():161-5. PubMed ID: 23662045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.
    Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM
    Lancet Respir Med; 2019 Mar; 7(3):239-248. PubMed ID: 30477763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.
    Tapson VF; McLaughlin VV; Gomberg-Maitland M; Widlitz AC; Krichman AD; Laliberte KJ; Zaccardelli DS; Barst RJ
    J Vasc Access; 2006; 7(3):112-7. PubMed ID: 17019662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
    Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
    Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable LENUS pro pump for treprostinil infusion in three pediatric patients.
    Álvarez-Fuente M; Garrido-Lestache E; Rivero N; Centella T; Lamas MJ; Pérez-Caballero C; Vázquez JL; Del Cerro MJ
    Pediatr Pulmonol; 2020 May; 55(5):1254-1258. PubMed ID: 32149476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.
    Reisbig KA; Coffman PA; Floreani AA; Bultsma CJ; Olsen KM
    Ann Pharmacother; 2005 Apr; 39(4):739-43. PubMed ID: 15755791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
    Mathier MA; McDevitt S; Saggar R
    J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
    Ivy DD; Claussen L; Doran A
    Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.